Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study

Chest. 2010 Jun;137(6):1405-9. doi: 10.1378/chest.09-2406. Epub 2010 Jan 15.


Background: Although there is now compelling evidence for cross-infection by strains of Pseudomonas aeruginosa at some specialist (cystic fibrosis [CF]) centers, the clinical impact of infection by transmissible strains is unclear.

Methods: In an 8-year prospective study, we compared the clinical outcome of two groups of patients with CF infected by transmissible (n = 28) and sporadic strains (n = 52) of P aeruginosa.

Results: There were no differences between the two groups in survival, annual changes in spirometry, or BMI. There were differences in requirements for IV antibiotic treatment (mean [SD]: 29.3 [21.9] days vs 53.1 [32.5] days) and hospitalization (median [range]: 11.6 [1.1, 49.3] days vs 23.3 [5.5, 103.6] days) between patients infected with sporadic and transmissible strains of P aeruginosa, respectively.

Conclusions: We conclude that infection by transmissible P aeruginosa does not increase mortality but is associated with increased health-care and antibiotic use for patients with CF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Chi-Square Distribution
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology
  • Cross Infection / microbiology*
  • Cystic Fibrosis / microbiology*
  • Female
  • Health Resources / statistics & numerical data
  • Humans
  • Male
  • Proportional Hazards Models
  • Prospective Studies
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology*
  • Statistics, Nonparametric
  • Treatment Outcome


  • Anti-Bacterial Agents